Navigation Links
Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
Date:1/8/2012

p>

10300672030839

0067203083

 100008460

Excedrin® Extra Strength  Tablets 125CT Bonus Pack New Carton

300672030863

10300672030860

0067203086

 100008022

Excedrin® Extra Strength  Tablets 200CT New Label

300672030924

10300672030921

0067203092

 100009062

Excedrin® Extra Strength  Tablets 24+6CT Bonus Pack

300672030306

10300672030303

0067203030

 100003181

Excedrin® Extra Strength  Tablets 24CT

300672030245

10300672030242

0067203024

 100008008

Excedrin® Extra Strength  Tablets 24CT New Label

300672030245

10300672030242

0067203024

 100008807

Excedrin® Extra Strength  Tablets 250+50CT Bonus Pack 

300672030573

10300672030570

0067203055

 100004173

Excedrin® Extra Strength  Tablets 250CT No Carton

300672030078

10300672030075

0067203007

 100008031

Excedrin® Extra Strength  Tablets 250CT No Carton New Label

300672030078

10300672030075

0067203007

 100004869

Excedrin® Extra Strength  Tablets 250CT Special Inners

300672030771

10300672030778

0067203077

 100008019

Excedrin® Extra Strength  Tablets 250CT New Label

300672030771

10300672030778

0067203077

 100007470

Excedrin® Extra Strength  Tablets 300CT New Carton

300672030337

10300672030310

0067203033

 100008472

Excedrin® Extra Strength  Tablets 300CT Club Tray

300672030337

10300672030310

0067203033


'/>"/>

SOURCE Novartis Consumer Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
2. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
3. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
4. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
5. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
6. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
7. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
8. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
9. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
10. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
11. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technology used to develop and produce enzymes ... biopharmaceuticals, and industrial enzymes industries, today announced the ... Bioenergy for commercial scale production of Abengoa,s proprietary ... developed under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... NEW YORK , October 1, 2014 ... and service provider for the medical industries, announced today the expansion ... New York City . genae Americas was incorporated ... is strategically centered in one of the highest concentrations of medical ... Philippe Kassab , President at genae Americas. "The expansion of genae ...
(Date:10/1/2014)... Oct. 1, 2014  Varian Medical Systems (NYSE: ... results for the fourth quarter of fiscal year 2014 ... 22, 2014.  The news release will be followed by ... p.m. PT.  The news release and a link to ... company website at: www.varian.com/investor .  To access the ...
Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3genae Opens Offices in New York City 2Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
... Sept. 9 Luminex Corporation (Nasdaq: LMNX ... Global Life Sciences Conference to be held September 20 ... (Logo:   http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) (Logo: ... Patrick J. Balthrop, president and chief executive officer, will ...
... NEW YORK, Sept. 9 Reportlinker.com announces that a new ... US Enzymes Market http://www.reportlinker.com/p091893/US-Enzymes-Market.html ... 2014 Demand for enzymes in the US is forecast to ... 2014. Solid industry growth in recent years has been founded ...
Cached Medicine Technology:Luminex Corporation to Present at UBS Global Life Sciences Conference 2Reportlinker Adds US Enzymes Market 2Reportlinker Adds US Enzymes Market 3Reportlinker Adds US Enzymes Market 4Reportlinker Adds US Enzymes Market 5Reportlinker Adds US Enzymes Market 6Reportlinker Adds US Enzymes Market 7Reportlinker Adds US Enzymes Market 8
(Date:10/1/2014)... Farmington Company today announced it has ... visual identity helping brokers, consultants and companies to ... create greater benefit communication synergies. They unveiled a ... customers to better leverage Farmington Company’s industry-tested experience ... the rebrand is the refreshed tagline: For the ...
(Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
(Date:10/1/2014)... Between 23 million and 50 million ... to figures from the National Institutes of Health (NIH) ... many of them have something else in common: They ... disease. Gluten Free Therapeutics, makers of CeliVites ... disease by publishing a series of blog posts aimed ...
(Date:10/1/2014)... City, NJ (PRWEB) October 01, 2014 Diet ... with their intentions to lose weight and their dieting attempts ... unhealthy, fatty foods. Including hormone diet treatments into ... only allows patients to see fast and effective weight loss ... and begin forming healthy habits to maintain their weight for ...
(Date:10/1/2014)... October 01, 2014 Anti Aging Clinic ... skin rejuvenating destination of choice, is announcing a discounted ... through to December. , “We’re doing this because we ... to our top skin clinic in Toronto,” says Dr. ... so much at Anti Aging Clinic, including laser facials, ...
Breaking Medicine News(10 mins):Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... -- Deadly and difficult to treat, liver cancer has long ... and prevent recurrence. But Mayo Clinic Cancer Center, in collaboration ... of Hepatology that the protein sulfatase 2 (SULF2) may provide ... new therapies. , Mayo Clinic Cancer Center leads the field ...
... Methodist Healthcare -- Memphis,Hospitals ("Methodist") announced today that ... designated maturities of the,Bonds. The tender offer was extended ... April 9, 2008 at 5:00 pm, New York City ... be terminated is applicable to,the following: for the Series ...
... CITY, Calif., April 10 Abaxis, Inc.,(Nasdaq: ... analysis systems, announced today that Clint Severson, Chief,Executive ... 37th,Annual Institutional Unconference on Tuesday, April 15, 2008 ... Atlanta, Georgia., Interested investors are invited to ...
... ANN ARBOR, Mich.---Female penguins mate with males who bring ... gain access to the most productive flowers guarded by ... affluent college students who don,t need resources will still ... Kruger, research scientist at the University of Michigan School ...
... trials could start in several years, study says , , THURSDAY, ... the formation of scar tissue at the site of a ... has been developed by researchers at Northwestern University in Chicago. ... to regrow after a spinal injury, but they,re blocked by ...
... inhibitors exhibit cancer-killing activities in cultured cells. While ... in clinical trials, just how they execute their ... of recent papers, Vanderbilt-Ingram Cancer Center investigators provide ... damage cancer cells and offer clues about possible ...
Cached Medicine News:Health News:Mayo Clinic identifies treatment target for liver cancer recurrence and survival 2Health News:Methodist Healthcare - Memphis Hospitals Announces Termination of Tender Offers 2Health News:Abaxis to Present at the SunTrust Robinson Humphrey's 37th Annual Institutional Unconference 2Health News:Just like penguins and other primates, people trade sex for resources 2Health News:Gel Enables Severed Spinal Cord Fibers to Regrow 2Health News:The good and bad side of anti-cancer compounds 2Health News:The good and bad side of anti-cancer compounds 3
... Strep A Test is a color immunochromatographic ... uses antibody labeled color particles coated at ... DLT allows greater sensitivity than the conventional ... the test procedure, a throat swab is ...
... The IntraLase FS laser introduces new high ... Surgeons now have the opportunity to offer ... to a microkeratome for creating the corneal ... FS laser and proprietary IntraLASIK software, surgeons ...
... Teco Diagnostics manufactures fine urine ... our urine chemistry reagent strips from ... to offer more economical prices compared ... the quality. Teco Diagnostics urine reagent ...
... term complications associated with diabetes continue to ... and quality of life of patients, in ... complications are known to be associated with ... that the level of haemoglobin A1c (HbA1c) ...
Medicine Products: